Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus
The first part of the paper deals with the relationship between two inhibiting factors of the complex enzyme cascade regulating fibrinolysis, namely plasminogen activator inhibitor type-1 (PAI-1) and lipoprotein(a) (Lp(a)). Blood concentrations of Lp(a), PAI-1 antigen (PAI-1 AG) and activity (PAI-1...
Gespeichert in:
| Veröffentlicht in: | Diabetes research and clinical practice 1996-07, Vol.33 (2), p.111-118 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 118 |
|---|---|
| container_issue | 2 |
| container_start_page | 111 |
| container_title | Diabetes research and clinical practice |
| container_volume | 33 |
| creator | Testa, R. Bonfigli, A.R. Piantanelli, L. Manfrini, S. Testa, I. Gregorio, F. |
| description | The first part of the paper deals with the relationship between two inhibiting factors of the complex enzyme cascade regulating fibrinolysis, namely plasminogen activator inhibitor type-1 (PAI-1) and lipoprotein(a) (Lp(a)). Blood concentrations of Lp(a), PAI-1 antigen (PAI-1 AG) and activity (PAI-1 AT), and the main parameters of lipo- and glyco-metabolic balance were studied in 80 type II diabetic patients. Roughly hyperbolic patterns have been found between PAI-1 and Lp(a). Negative statistically significant linear correlation can be elicited when Log PAI-1 AG and Log PAI-1 AT values are plotted versus Lp(a) values, the first one being particularly tight. These findings suggest a nearly on/off control of the two parameters, limiting the risk of hypofibrinolysis. The second part of the paper was aimed at verifying this hypothesis. A group of 30 diabetic patients were treated for 3 months with metformin, an antidiabetic biguanide compound which has been reported to reduce PAI-1 levels both in diabetic and in non-diabetic patients. Metformin significantly reduced PAI-1 AG and PAI-1 AT but did not influence plasma Lp(a) levels. A clear linear correlation between the basal Lp(a) values and the changes in PAI-1 AG levels was found. An even tighter correlation was elicited between the decrease in PAI-1, and PAI-1 pretreatment values. |
| doi_str_mv | 10.1016/0168-8227(96)01286-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78460956</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0168822796012867</els_id><sourcerecordid>78460956</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-ccd3e4e27a79bdd02002e8f386d307f7544e3eca291c2f54586ffd98513d2fa73</originalsourceid><addsrcrecordid>eNp9UcGOFCEUJEazzq7-gSYcjNk9tALdDfTFxGxcNdnExOiZMPDawdDQAj1mf8WvlbYnc_RAeFBFvaIeQi8oeUMJ5W_rko1kTFwP_IZQJnkjHqEdlYL9u36MdmfKU3SZ809CCG-7_gJdSCmGgfMd-vMVvC4uhnxwM95D-Q0Q8Ox1nlyIP2qtTXFHXWLCLhzc3q1VeZihoRtNYw9H8BnrYHE5APZujnOKBVy41jfYxGAglLR1qSI4xNC4kBfvQmNhhmArjq3TtT1kPIH3riz5GXoyap_h-Wm_Qt_vPny7_dTcf_n4-fb9fWNayUtjjG2hAya0GPbWEkYIAzlWzLZEjKLvOmjBaDZQw8a-6yUfRzvInraWjVq0V-j1pltN_1ogFzW5bKoJHSAuWQnZcTL0vBK7jWhSzDnBqObkJp0eFCVqHYla81Zr3mpYD3UkatV_edJf9hPY86PTDCr-6oTrbLQfkw7G5TOtZeuXaKW922g1azg6SCobBzVb6xKYomx0__fxFyhGrCY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78460956</pqid></control><display><type>article</type><title>Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Testa, R. ; Bonfigli, A.R. ; Piantanelli, L. ; Manfrini, S. ; Testa, I. ; Gregorio, F.</creator><creatorcontrib>Testa, R. ; Bonfigli, A.R. ; Piantanelli, L. ; Manfrini, S. ; Testa, I. ; Gregorio, F.</creatorcontrib><description>The first part of the paper deals with the relationship between two inhibiting factors of the complex enzyme cascade regulating fibrinolysis, namely plasminogen activator inhibitor type-1 (PAI-1) and lipoprotein(a) (Lp(a)). Blood concentrations of Lp(a), PAI-1 antigen (PAI-1 AG) and activity (PAI-1 AT), and the main parameters of lipo- and glyco-metabolic balance were studied in 80 type II diabetic patients. Roughly hyperbolic patterns have been found between PAI-1 and Lp(a). Negative statistically significant linear correlation can be elicited when Log PAI-1 AG and Log PAI-1 AT values are plotted versus Lp(a) values, the first one being particularly tight. These findings suggest a nearly on/off control of the two parameters, limiting the risk of hypofibrinolysis. The second part of the paper was aimed at verifying this hypothesis. A group of 30 diabetic patients were treated for 3 months with metformin, an antidiabetic biguanide compound which has been reported to reduce PAI-1 levels both in diabetic and in non-diabetic patients. Metformin significantly reduced PAI-1 AG and PAI-1 AT but did not influence plasma Lp(a) levels. A clear linear correlation between the basal Lp(a) values and the changes in PAI-1 AG levels was found. An even tighter correlation was elicited between the decrease in PAI-1, and PAI-1 pretreatment values.</description><identifier>ISSN: 0168-8227</identifier><identifier>EISSN: 1872-8227</identifier><identifier>DOI: 10.1016/0168-8227(96)01286-7</identifier><identifier>PMID: 8879966</identifier><identifier>CODEN: DRCPE9</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Aged ; Biological and medical sciences ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - metabolism ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; Fibrinolysis ; Humans ; Hypoglycemic Agents - pharmacology ; Hypoglycemic Agents - therapeutic use ; Linear Models ; Lipoprotein(a) ; Lipoprotein(a) - blood ; Lipoprotein(a) - drug effects ; Male ; Medical sciences ; Metformin - pharmacology ; Metformin - therapeutic use ; Middle Aged ; Non-insulin-dependent diabetes mellitus ; Plasminogen Activator Inhibitor 1 - blood ; Plasminogen Activator Inhibitor 1 - metabolism ; Plasminogen activator inhibitor type 1 ; Serine Proteinase Inhibitors - blood ; Serine Proteinase Inhibitors - metabolism</subject><ispartof>Diabetes research and clinical practice, 1996-07, Vol.33 (2), p.111-118</ispartof><rights>1996</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-ccd3e4e27a79bdd02002e8f386d307f7544e3eca291c2f54586ffd98513d2fa73</citedby><cites>FETCH-LOGICAL-c386t-ccd3e4e27a79bdd02002e8f386d307f7544e3eca291c2f54586ffd98513d2fa73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0168-8227(96)01286-7$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3202001$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8879966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Testa, R.</creatorcontrib><creatorcontrib>Bonfigli, A.R.</creatorcontrib><creatorcontrib>Piantanelli, L.</creatorcontrib><creatorcontrib>Manfrini, S.</creatorcontrib><creatorcontrib>Testa, I.</creatorcontrib><creatorcontrib>Gregorio, F.</creatorcontrib><title>Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus</title><title>Diabetes research and clinical practice</title><addtitle>Diabetes Res Clin Pract</addtitle><description>The first part of the paper deals with the relationship between two inhibiting factors of the complex enzyme cascade regulating fibrinolysis, namely plasminogen activator inhibitor type-1 (PAI-1) and lipoprotein(a) (Lp(a)). Blood concentrations of Lp(a), PAI-1 antigen (PAI-1 AG) and activity (PAI-1 AT), and the main parameters of lipo- and glyco-metabolic balance were studied in 80 type II diabetic patients. Roughly hyperbolic patterns have been found between PAI-1 and Lp(a). Negative statistically significant linear correlation can be elicited when Log PAI-1 AG and Log PAI-1 AT values are plotted versus Lp(a) values, the first one being particularly tight. These findings suggest a nearly on/off control of the two parameters, limiting the risk of hypofibrinolysis. The second part of the paper was aimed at verifying this hypothesis. A group of 30 diabetic patients were treated for 3 months with metformin, an antidiabetic biguanide compound which has been reported to reduce PAI-1 levels both in diabetic and in non-diabetic patients. Metformin significantly reduced PAI-1 AG and PAI-1 AT but did not influence plasma Lp(a) levels. A clear linear correlation between the basal Lp(a) values and the changes in PAI-1 AG levels was found. An even tighter correlation was elicited between the decrease in PAI-1, and PAI-1 pretreatment values.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Female</subject><subject>Fibrinolysis</subject><subject>Humans</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Linear Models</subject><subject>Lipoprotein(a)</subject><subject>Lipoprotein(a) - blood</subject><subject>Lipoprotein(a) - drug effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metformin - pharmacology</subject><subject>Metformin - therapeutic use</subject><subject>Middle Aged</subject><subject>Non-insulin-dependent diabetes mellitus</subject><subject>Plasminogen Activator Inhibitor 1 - blood</subject><subject>Plasminogen Activator Inhibitor 1 - metabolism</subject><subject>Plasminogen activator inhibitor type 1</subject><subject>Serine Proteinase Inhibitors - blood</subject><subject>Serine Proteinase Inhibitors - metabolism</subject><issn>0168-8227</issn><issn>1872-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UcGOFCEUJEazzq7-gSYcjNk9tALdDfTFxGxcNdnExOiZMPDawdDQAj1mf8WvlbYnc_RAeFBFvaIeQi8oeUMJ5W_rko1kTFwP_IZQJnkjHqEdlYL9u36MdmfKU3SZ809CCG-7_gJdSCmGgfMd-vMVvC4uhnxwM95D-Q0Q8Ox1nlyIP2qtTXFHXWLCLhzc3q1VeZihoRtNYw9H8BnrYHE5APZujnOKBVy41jfYxGAglLR1qSI4xNC4kBfvQmNhhmArjq3TtT1kPIH3riz5GXoyap_h-Wm_Qt_vPny7_dTcf_n4-fb9fWNayUtjjG2hAya0GPbWEkYIAzlWzLZEjKLvOmjBaDZQw8a-6yUfRzvInraWjVq0V-j1pltN_1ogFzW5bKoJHSAuWQnZcTL0vBK7jWhSzDnBqObkJp0eFCVqHYla81Zr3mpYD3UkatV_edJf9hPY86PTDCr-6oTrbLQfkw7G5TOtZeuXaKW922g1azg6SCobBzVb6xKYomx0__fxFyhGrCY</recordid><startdate>19960701</startdate><enddate>19960701</enddate><creator>Testa, R.</creator><creator>Bonfigli, A.R.</creator><creator>Piantanelli, L.</creator><creator>Manfrini, S.</creator><creator>Testa, I.</creator><creator>Gregorio, F.</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960701</creationdate><title>Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus</title><author>Testa, R. ; Bonfigli, A.R. ; Piantanelli, L. ; Manfrini, S. ; Testa, I. ; Gregorio, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-ccd3e4e27a79bdd02002e8f386d307f7544e3eca291c2f54586ffd98513d2fa73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Female</topic><topic>Fibrinolysis</topic><topic>Humans</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Linear Models</topic><topic>Lipoprotein(a)</topic><topic>Lipoprotein(a) - blood</topic><topic>Lipoprotein(a) - drug effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metformin - pharmacology</topic><topic>Metformin - therapeutic use</topic><topic>Middle Aged</topic><topic>Non-insulin-dependent diabetes mellitus</topic><topic>Plasminogen Activator Inhibitor 1 - blood</topic><topic>Plasminogen Activator Inhibitor 1 - metabolism</topic><topic>Plasminogen activator inhibitor type 1</topic><topic>Serine Proteinase Inhibitors - blood</topic><topic>Serine Proteinase Inhibitors - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Testa, R.</creatorcontrib><creatorcontrib>Bonfigli, A.R.</creatorcontrib><creatorcontrib>Piantanelli, L.</creatorcontrib><creatorcontrib>Manfrini, S.</creatorcontrib><creatorcontrib>Testa, I.</creatorcontrib><creatorcontrib>Gregorio, F.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes research and clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Testa, R.</au><au>Bonfigli, A.R.</au><au>Piantanelli, L.</au><au>Manfrini, S.</au><au>Testa, I.</au><au>Gregorio, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus</atitle><jtitle>Diabetes research and clinical practice</jtitle><addtitle>Diabetes Res Clin Pract</addtitle><date>1996-07-01</date><risdate>1996</risdate><volume>33</volume><issue>2</issue><spage>111</spage><epage>118</epage><pages>111-118</pages><issn>0168-8227</issn><eissn>1872-8227</eissn><coden>DRCPE9</coden><abstract>The first part of the paper deals with the relationship between two inhibiting factors of the complex enzyme cascade regulating fibrinolysis, namely plasminogen activator inhibitor type-1 (PAI-1) and lipoprotein(a) (Lp(a)). Blood concentrations of Lp(a), PAI-1 antigen (PAI-1 AG) and activity (PAI-1 AT), and the main parameters of lipo- and glyco-metabolic balance were studied in 80 type II diabetic patients. Roughly hyperbolic patterns have been found between PAI-1 and Lp(a). Negative statistically significant linear correlation can be elicited when Log PAI-1 AG and Log PAI-1 AT values are plotted versus Lp(a) values, the first one being particularly tight. These findings suggest a nearly on/off control of the two parameters, limiting the risk of hypofibrinolysis. The second part of the paper was aimed at verifying this hypothesis. A group of 30 diabetic patients were treated for 3 months with metformin, an antidiabetic biguanide compound which has been reported to reduce PAI-1 levels both in diabetic and in non-diabetic patients. Metformin significantly reduced PAI-1 AG and PAI-1 AT but did not influence plasma Lp(a) levels. A clear linear correlation between the basal Lp(a) values and the changes in PAI-1 AG levels was found. An even tighter correlation was elicited between the decrease in PAI-1, and PAI-1 pretreatment values.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>8879966</pmid><doi>10.1016/0168-8227(96)01286-7</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8227 |
| ispartof | Diabetes research and clinical practice, 1996-07, Vol.33 (2), p.111-118 |
| issn | 0168-8227 1872-8227 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78460956 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Biological and medical sciences Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Diabetes. Impaired glucose tolerance Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Fibrinolysis Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Linear Models Lipoprotein(a) Lipoprotein(a) - blood Lipoprotein(a) - drug effects Male Medical sciences Metformin - pharmacology Metformin - therapeutic use Middle Aged Non-insulin-dependent diabetes mellitus Plasminogen Activator Inhibitor 1 - blood Plasminogen Activator Inhibitor 1 - metabolism Plasminogen activator inhibitor type 1 Serine Proteinase Inhibitors - blood Serine Proteinase Inhibitors - metabolism |
| title | Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T10%3A13%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relationship%20between%20plasminogen%20activator%20inhibitor%20type-1%20plasma%20levels%20and%20the%20lipoprotein(a)%20concentrations%20in%20non-insulin-dependent%20diabetes%20mellitus&rft.jtitle=Diabetes%20research%20and%20clinical%20practice&rft.au=Testa,%20R.&rft.date=1996-07-01&rft.volume=33&rft.issue=2&rft.spage=111&rft.epage=118&rft.pages=111-118&rft.issn=0168-8227&rft.eissn=1872-8227&rft.coden=DRCPE9&rft_id=info:doi/10.1016/0168-8227(96)01286-7&rft_dat=%3Cproquest_cross%3E78460956%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78460956&rft_id=info:pmid/8879966&rft_els_id=0168822796012867&rfr_iscdi=true |